Bradley L. Campbell - Jan 2, 2023 Form 4 Insider Report for AMICUS THERAPEUTICS, INC. (FOLD)

Role: President & CEO, Director
Signature: /s/ Christian Formica, Attorney-in-Fact
Stock symbol: FOLD
Transactions as of: Jan 2, 2023
Transactions value $: -$563,933
Form type: 4
Date filed: 1/4/2023, 06:10 PM
Previous filing: Dec 5, 2022
Next filing: Jan 6, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	FOLD	Common Stock	Tax liability	-$337K	-27.6K	-4%	$12.21	662K	Jan 2, 2023	Direct
transaction	FOLD	Common Stock	Award	$0	+170K	+25.62%	$0.00	832K	Jan 3, 2023	Direct	F1
transaction	FOLD	Common Stock	Tax liability	-$227K	-19K	-2.29%	$11.93	813K	Jan 3, 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	FOLD	Stock Options (right to buy)	Award	$0	+301K		$0.00	301K	Jan 3, 2023	Common Stock	301K	$11.93	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in four equal annual installments beginning on January 3, 2024 and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock.
F2	These options vest and become exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter.